New Aspects of Neuroblastoma Treatment: ASPHO 2011 Symposium Review

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2012 Mar 2

PMID 22378620

Citations 11

Authors

Peter E Zage

Chrystal U Louis

Susan L Cohn

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood, and the outcomes for children with high-risk and relapsed disease remain poor. However, new international strategies for risk stratification and for treatment based on novel tumor targets and including immunotherapy are being employed in attempts to improve the outcomes of children with neuroblastoma. A new international neuroblastoma risk classification system has been developed which is being incorporated into cooperative group clinical trials in North America, Japan, and Europe, resulting in standardized approaches for the initial evaluation and treatment stratification of neuroblastoma patients. Furthermore, novel treatment regimens are being developed based on improved understanding of neuroblastoma biology and on the recruitment of the immune system to specifically target neuroblastoma tumors. These approaches will lead to new therapeutic strategies that likely will improve the outcomes for children with neuroblastoma worldwide.

Citing Articles

Applications and prospects of targeted therapy for neuroblastoma.

Wang J, Yao W, Li K World J Pediatr Surg. 2022; 3(2):e000164.

PMID: 36474924 PMC: 9716989. DOI: 10.1136/wjps-2020-000164.

A model of modified -iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment.

Saimuang K, Suttisintong K, Kaewchangwat N, Thanayupong E, Wongngam Y, Charoenphun P RSC Adv. 2022; 11(41):25199-25206.

PMID: 35478920 PMC: 9037022. DOI: 10.1039/d1ra04054e.

CHL1 and NrCAM are Primarily Expressed in Low Grade Pediatric Neuroblastoma.

Wachowiak R, Mayer S, Suttkus A, Martynov I, Lacher M, Melling N Open Med (Wars). 2020; 14:920-927.

PMID: 31989042 PMC: 6972343. DOI: 10.1515/med-2019-0109.

GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.

Cournoyer S, Addioui A, Belounis A, Beaunoyer M, Nyalendo C, Le Gall R BMC Cancer. 2019; 19(1):1018.

PMID: 31664947 PMC: 6819521. DOI: 10.1186/s12885-019-6195-y.

In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

Yavuz B, Zeki J, Coburn J, Ikegaki N, Levitin D, Kaplan D J Control Release. 2018; 285:162-171.

PMID: 30018030 PMC: 6098973. DOI: 10.1016/j.jconrel.2018.07.002.

References

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

Wei J, Johansson P, Chen Q, Song Y, Durinck S, Wen X . microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res. 2009; 15(17):5560-8. PMC: 2737097. DOI: 10.1158/1078-0432.CCR-08-3287. View

Brodeur G, Seeger R, Barrett A, Berthold F, Castleberry R, DAngio G . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988; 6(12):1874-81. DOI: 10.1200/JCO.1988.6.12.1874. View

Oppenheimer O, Cheung N, Gerald W . The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007; 6(4):1300-9. DOI: 10.1158/1535-7163.MCT-06-0587. View

Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R . Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006; 24(31):5070-8. DOI: 10.1200/JCO.2006.06.1879. View

Rousseau R, Haight A, Hirschmann-Jax C, Yvon E, Rill D, Mei Z . Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2002; 101(5):1718-26. DOI: 10.1182/blood-2002-08-2493. View

Macarulla T, Ramos F, Tabernero J . Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008; 3(2):114-22. DOI: 10.2174/157489208784638785. View

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N . Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2008; 15(1):67-78. DOI: 10.1016/j.ccr.2008.12.005. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

10.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

11.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

12.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y . Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol. 2010; 28(21):3506-15. DOI: 10.1200/JCO.2009.27.3367. View

13.

Lin E, Li L, Guan Y, Soriano R, Rivers C, Mohan S . Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009; 7(9):1466-76. DOI: 10.1158/1541-7786.MCR-08-0522. View

14.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

15.

Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano G, De Sio L . Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl. 2004; 93(445):6-11. DOI: 10.1111/j.1651-2227.2004.tb03048.x. View

16.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J . Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009; 10(7):663-71. PMC: 3045079. DOI: 10.1016/S1470-2045(09)70154-8. View

17.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

18.

Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J . A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother. 1992; 35(3):199-204. PMC: 11038881. DOI: 10.1007/BF01756188. View

19.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

20.

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View